Einfluß von unfraktioniertem Heparin auf die Plättchenfunktion und primäre Hämostase^[*]

• LITERATUR

• 1 Rosenberg R. D. Actions and interactions of antithrombin and heparin. New Engl. J. Med. 292: 146-151 1975;
• 2 Babcock R. B, Dumper C. W, Scharfman W. B. Heparin-induced immune thrombocytopenia. New Engl. J. Med. 295: 237-241 1976;
• 3 Cimino R. L, Moake J. L, Weininger R. S, Ben-Menachem Y, Khalil K. G. Amer. J. Haematol. 06: 125-133 1979;
• 4 Rhodes G. R, Dixon R. H, Silver D. Heparin-induced thrombocytopenia: Eight cases with thrombotic-hemorrhagic complication. Ann. Surg. 186: 752-758 1977;
• 5 Besterman E. M. M, Gillett M RT. Heparin effects on plasma lysolecithin formation and platelet aggregation. Atherosclerosis 17: 503-513 1973;
• 6 O’Brien J. H, Shoobridge S. M, Finch W. J. Comparison of the effect of heparin and citrate on platelet aggregation. J. Clin. Path. 22: 28-31 1969;
• 7 Thomson C, Forbes D. C, Prentice C. R. M. The potentiation of platelet aggregation and adhesion by heparin in vitro and in vivo. Clin. Sci. Mol. Med. 45: 485-494 1973;
• 8 Eika C. Platelet refractory state induced by heparin. Scand. J. Haemat. 09: 665-672 1972;
• 9 Beck E. Effects of heparin on platelet reactivity in citrated plasma. Thrombos. Haemostas 38: 578-580 1977;
• 10 Mastacchi R, Stanzani L, Barbanti M, Montecchi L, Bianchini P. Interaction of heparin and fractions with human platelets. Thromb. Res. 28: 275-280 1982;
• 11 Salzman E. W, Rosenberg R. D, Smith M. H, Lindon J. N, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J. Clin. Invest. 65: 64-73 1980;
• 12 Praga C. Standardized bleeding time in the study of drugs interferring with platelet function. Adv. Exp. Med. Biol. 34: 149-158 1972;
• 13 Born G. V. R. Quantitative investigations into the aggregation of blood platelets. J. Physiol. 162: 67-77 1962;
• 14 Born G. V. R, Cross M. J. The aggregation of blood platelets. J. Physiol. 168: 178-195 1963;
• 15 Heinrich D, Gutschank S, MuellerEckhardt C. HLA-Antibody-induced 14c-serotonin release from platelets. A methodological analysis. Vox. Sang. 33: 65-78 1977;
• 16 Röka L. Anwendung chromogener Substrate zur Bestimmung von Heparin-Kofaktor (Antithrombin III) und Heparin. Krankenhausarzt. 52: 871-879 1979;
• 17 Gladke E, von Hattingberg H. M. Pharmakokinetik. Eine Einführung. Springer, Berlin Heidelberg New York: 1973: 39-43.
• 18 Biggs R. In: Human Blood Coagulation, Haemostasis and Thrombosis. Blackwell Scientific; Oxford: 1972
• 19 Quick A. J, Schanberg J. N, Stefanini M. The effect of heparin on platelets in vivo. J. Lab. Clin. Med. 33: 1424-1430 1948;
• 20 Borchgrevink C. E. The mechanism of the prolonged bleeding time provoked by dextran sulfate or by excessive doses of heparin. Acta Med. Scand. 170: 365-373 1961;
• 21 Heiden D, Mielke C. H, Rodvien R. Impairment by heparin of primary haemostasis and platelet ¹⁴C-5-hydroxytryptamin release. Brit. J. Haematol. 36: 427-436 1977;
• 22 Gillett M. P. T, Besterman E. M. M. Effects of heparin derived from different tissues on plasma phospholipides and platelet aggregation. Lancet. II: 1204 1973;
• 23 Eika C. On the mechanism of platelet aggregation induced by heparin, protamin and polybrene. Scand. J. Haematol. 09: 248-257 1972;
• 24 Zucker M. G. Heparin and platelet function. Fed. Proc. 36: 47-49 1977;
• 25 Heinrich D. (unveröffentlichte Mitteilung).
• 26 Shanberge J. N, Kambayashi J, Nakagawa M. The interaction of platelets with a tritium-labeled heparin. Thromb. Res. 09: 595-601 1976;
• 27 Lindon J. N, Brier-Russell D, Silane M, Smith M. H, Labarre D, Dincer A, Rosenberg R. D, Merrill E, Salzman E. W. Heparin-coated surfaces that bind antithrombin have reduced platelet reactivity. Thromb. Haemost. 42: 131-136 1979;
• 28 Rosenberg R. D. Heparin-antithrombin system. In: Colman R. W, Hirsh J, Marder V. J, Salzman E. W. (Eds.): Hemostasis and Thrombosis. Lippincott; Philadelphia Toronto: 1982: 962-985.
• 29 Coller B. W, Gralnick H. R. Studies on the mechanism of ristocetin-induced platelet agglutination. Effects of structural modification of ristocetin and vancomycin. J. Clin. Invest. 60: 302-307 1977;
• 30 Amsterdam A, Reches A, Amir Y, Mintz Y, Salomon Y. Modulation of adenylcyclase activity by sulfated glycosaminoglycane. II. Effects of mucopolysaccharides and dextran on the activity of adenylate cyclase derived from various tissues. Biochim. Biophys. Acta. 544: 273-283 1978;
• 31 Saba H. I, Saba S. R, Blackburn C. A, Hartmann R. C, Mason R. G. Heparin neutralization of PGI₂: Effect upon platelets. Science 205: 499-501 1977;
• 32 Eldor A, Weksler B. B. Heparin and dextran sulfate antagonize PGI₂ inhibition of platelet aggregation. Thromb. Res. 16: 617-628 1979;
• 33 Lewy R. U, Wiener L, Smith J. B, Walinsky P, Silver M. J. Intravenous heparin initiates in vivo synthesis and release of thromboxane in angina pectoris. Lancet II: 97 1979;
• 34 Anderson A, Mohammad W. H, Chuang H. Y. K, Mason R. G. Heparin potentiates synthesis of thromboxane A₂ in human platelets. Adv. Prostaglandin Thromboxane Res. 06: 287-291 1980;
• 35 Mohammad S. K, Anderson W. H, Smith J. B, Chuang H. Y. K, Mason R. G. Effects of heparin on platelet aggregation and release and thromboxane A₂ production. Amer. J. Pathol. 104: 132-141 1981;
• 36 Ansell J, Slepchuk Jr. N, Kumar R, Copez A, Deykin D. Heparin-induced thrombocytopenia: A prospective study. Haemostasis 43: 61-65 1980;
• 37 Bell W. R, Tomasulo P. A, Alving B. M, Duffy R. P. Thrombocytopenia occurring during the administration of heparin. A prospective study in 52 patients. Ann. Intern. Med. 85: 155-160 1976;
• 38 Kapsch D. N, Adelstein E. H, Rhodes G. R, Silver D. Heparin-induced thrombocytopenia, thrombosis and haemorrhage. Surgery 86: 148-155 1979;
• 39 Klein H. G, Bell W. R. Disseminated intravascular coagulation during heparintherapy. Ann. Intern. Med. 80: 477-481 1974;
• 40 Rhodes G. R, Dixon R. H, Silver D. Heparin-induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg. Gynecol. Obstet. 136: 409-416 1973;
• 41 Bell W. R, Anderson N. D, Anderson A. D. Heparin-induced coagulopathy. J. Lab. Clin. Med. 89: 741-750 1977;
• 42 Heinrich D, Schleussner E, Wagner W. L, Sellmann-Richter R, Hehrlein F. W. Prostacyclin in aortocoronary bypass surgery: A double-blind, placebocontrolled study. Thromb. Res. 32: 409-426 1983;
• 43 Ditter H, Heinrich D, Matthias F. R, Sellmann-Richter R, Wagner W. L, Hehrlein F. W. Effects of prostaglandin during cardiopulmonary bypass in man on plasma levels of ß-thromboglobulin, platelet factor 4, thromboxane A₂, 6-Keto-prostaglandin Fla and heparin. Thromb. Res. 32: 393-408 1983;